biotech
Commented by Matthias Schomber on October 23rd, 2026 | 05:42 CEST
Puma Boardroom Shake-Up, Margin Pressure at BYD and Clinical Milestones at BioNxt Solutions
Sportswear manufacturer Puma is pressing ahead with its strategic realignment following a change of ownership and the arrival of Anta Sports as a shareholder. Chinese electric vehicle group BYD is grappling with regulatory hurdles and declining export margins. In the advanced drug delivery segment, BioNxt Solutions is attracting investors' attention with clinical progress and an interesting chart pattern. This article analyses the opportunities and risks of these three stocks. A close look at their fundamentals and technicals shows where key entry and turning points could lie for investors in the coming days and weeks.
Read
Commented by Fabian Lorenz on October 23rd, 2026 | 05:38 CEST
Strong News and Buy Recommendations: Vonovia, Evotec and Lahontan Gold
Strong news from Lahontan Gold. The explorer has published a positive preliminary economic assessment (PEA) for its Santa Fe gold-silver project in Nevada. The after-tax net present value stands at approximately USD 820 million, significantly exceeding the company's current market capitalisation. The company is also working to expand the resource base. While Lahontan Gold shareholders can look forward to the approaching start of gold production, Vonovia shareholders face an uncertain future. The expropriation scenario is weighing on sentiment. Even JPMorgan's assessment that these concerns are exaggerated does little to change the picture. In a worst-case scenario, the German government would intervene. And what about Evotec? The shares have gained more than 10% in recent trading days. The appointment of a new executive at Novo Nordisk could inject fresh momentum into the company.
Read